Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 5

1.

Single-chain Fv-streptavidin substantially improved therapeutic index in multistep targeting directed at disialoganglioside GD2.

Cheung NK, Modak S, Lin Y, Guo H, Zanzonico P, Chung J, Zuo Y, Sanderson J, Wilbert S, Theodore LJ, Axworthy DB, Larson SM.

J Nucl Med. 2004 May;45(5):867-77.

3.

Pretargeted radioimmunotherapy of cancer: progress step by step.

Boerman OC, van Schaijk FG, Oyen WJ, Corstens FH.

J Nucl Med. 2003 Mar;44(3):400-11. Review.

4.

Anti-GD2 monoclonal antibody immunotherapy: a promising strategy in the prevention of neuroblastoma relapse.

Raffaghello L, Marimpietri D, Pagnan G, Pastorino F, Cosimo E, Brignole C, Ponzoni M, Montaldo PG.

Cancer Lett. 2003 Jul 18;197(1-2):205-9. Review.

PMID:
12880983
5.

Disialoganglioside GD2 as a therapeutic target for human diseases.

Suzuki M, Cheung NK.

Expert Opin Ther Targets. 2015 Mar;19(3):349-62. doi: 10.1517/14728222.2014.986459. Epub 2015 Jan 20. Review.

PMID:
25604432

Supplemental Content

Support Center